Circulating matrix metalloproteinases and their inhibitors in hypertension

dc.creatorFontana, Vanessa
dc.creatorSilva, Pamela S.
dc.creatorGerlach, Raquel F.
dc.creatorTanus-Santos, Jose E.
dc.date2012
dc.date2013-09-19T18:05:51Z
dc.date2016-07-01T15:17:33Z
dc.date2013-09-19T18:05:51Z
dc.date2016-07-01T15:17:33Z
dc.date.accessioned2018-03-29T01:55:37Z
dc.date.available2018-03-29T01:55:37Z
dc.identifierClinica Chimica Acta. Elsevier, v.413, n.41493, p.656-662, 2012
dc.identifier0009-8981
dc.identifierWOS:000301908000002
dc.identifier10.1016/j.cca.2011.12.021
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/1790
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/1790
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1308846
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.descriptionGrowing experimental evidence indicates that matrix metalloproteinases (MMPs) are implicated in many cardiovascular diseases including hypertension and its chronic complications. It is now clear that MMPs have many more substrates other than components of the extracellular matrix. In fact, intracellular targets now include those associated with the cardiovascular system. Clinical studies have suggested that circulating MMPs may predict cardiovascular morbidity and mortality. It is highly probable that increased MMPs may predispose hypertensive patients to additional complications and clinical sequelae. In this article, we review the basic principles linking MMP activity with hypertension and summarize clinical studies examining two specific MMPs (MMP-2 and -9) in hypertension. We also discuss how antihypertensive drugs may affect MMPs and their endogenous inhibitors, i.e., tissue inhibitors of matrix metalloproteinases (TIMPs). Circulating MMPs may predict increased risk of developing cardiovascular complications associated with hypertension. As such, patients could benefit from early pharmacologic intervention including use of MMP inhibitors. (C) 2012 Elsevier B.V. All rights reserved.
dc.description413
dc.description07/ago
dc.description656
dc.description662
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.descriptionCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.languageeng
dc.publisherElsevier
dc.publisherAmsterdam
dc.relationClinica Chimica Acta
dc.rightsfechado
dc.sourceWOS
dc.subjectHypertension
dc.subjectMatrix metalloproteinases
dc.subjectTissue inhibitors of matrix metalloproteinases
dc.subjectACUTE MYOCARDIAL-INFARCTION
dc.subjectNECROSIS-FACTOR-ALPHA
dc.subjectCARDIOVASCULAR RISK-FACTORS
dc.subjectPREVENTS CARDIAC RUPTURE
dc.subjectSMALL ARTERY STRUCTURE
dc.subjectTISSUE INHIBITORS
dc.subjectVASCULAR DYSFUNCTION
dc.subjectENDOTHELIAL-CELLS
dc.subjectTARGETED DELETION
dc.subjectPLASMA MATRIX-METALLOPROTEINASE-9
dc.titleCirculating matrix metalloproteinases and their inhibitors in hypertension
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución